Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: A pooled analysis of three studies conducted in North America and Europe

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 4, 2013, Pages 264-273

  Nelson, Anita ^a   Parke, Susanne ^b   Makalova, Dagmar ^c   Serrani, Marco ^d   Palacios, Santiago ^e   Mellinger, Uwe ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Global Clinical Development   (Germany)

^c Femina Sana Sro Clinic of Obstetrics   (Czech Republic)

^d Bayer Healthcare   (Germany)

^e Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

Author keywords

Cycle control; Oestradiol; Oral contraceptive; Uterine bleeding

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE;

ACNE; ADULT; ARTICLE; BLEEDING; CONTRACEPTION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; LIBIDO DISORDER; LIGHT INTENSITY; MAJOR CLINICAL STUDY; METRORRHAGIA; NODULAR HYPERPLASIA; OCULAR HISTOPLASMOSIS; OVARY CYST; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHINOPHARYNGITIS; UTERUS MYOMA; WITHDRAWAL BLEEDING;

ADOLESCENT; ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; CONTRACEPTION; CONTRACEPTIVES, ORAL; DRUG COMBINATIONS; ESTRADIOL; EUROPE; FEMALE; HUMANS; MENSTRUATION; METRORRHAGIA; MIDDLE AGED; NANDROLONE; NORTH AMERICA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880291290     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.780202     Document Type: Article

References (35)

1. Warner Chilcott. Lo Loestrin Fe. Highlights of prescribing information. 2012. Accessed 28 January from: http://www.wcrx.com/pdfs/pi/pi-loloestrinfe.pdf.
2. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78. (Pubitemid 43231449)
3. Kiley J , Hammond C. Combined oral contraceptives: A comprehensive review. Clin Obstet Gynecol 2007;50:868-77. (Pubitemid 350059283)
4. Fruzzetti F. Beyaz ® :An oral contraceptive fortifi ed with folate. Womens Health (Lond Engl) 2012;8:13-9.
5. Rapkin R B , Creinin M D. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opin Pharmacother 2011;12:2403-10.
6. Nakajima ST, Archer DF, Ellman H. Effi cacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007;75:16-22. (Pubitemid 44854856)
7. Hoy S M, Scott L J. Estradiol valerate/dienogest in oral contraception. Drugs 2009;69:1635-46.
8. Astedt B, Jeppsson S , Liedholm P , et a l. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 β-oestradiol. Br J Obstet Gynaecol 1979;86:732-6. (Pubitemid 9245029)
9. Kivinen S, Saure A. Effi cacy and tolerability of a combined oral contraceptive containing 17 β-estradiol and desogestrel. Eur J Contracept Reprod Health Care 1996;1:183.
10. Koetsawang S , Mandlekar A , Krishna U , et a l. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. Contraception 1980;21:445-59. (Pubitemid 10068906)
11. Schubert W , Cullberg G. Ovulation inhibition with 17 β-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand 1987;66:543-7. (Pubitemid 18014725)
12. Serup J, Bostofte E , Larsen S, et al. Natural oestrogens for oral contraception. Lancet 1979;2:471-2. (Pubitemid 9250419)
13. Wenzl R, Bennink HC, van Beek A , et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 β-estradiol. Fertil Steril 1993;60:616-9. (Pubitemid 23298503)
14. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82. (Pubitemid 28447229)
15. Endrikat J, Parke S , Trummer D , et a l. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: Results of two prospective, randomized, open-label studies. Contraception 2008;78:218-25.
16. Palacios S , W ildt L , P arke S , et a l. Effi cacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010;149:57-62.
17. Ahrendt HJ, Makalova D , Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009;80:436-44.
18. Sasagawa S. , Shimizu Y , Kami H , et a l. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its effi cient pharmacokinetic profi le. Steroids 2008;73:222-31.
19. Oettel M, Breitbarth W , Elgar W , et al. The pharmacological profi le of dienogest. Eur J Contracept Reprod Health Care 1999;4:2-13.
20. Okada H, Nakajima T, Yoshimura T, et al. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod 2001;7:341-7. (Pubitemid 32288323)
21. Guida M, Bifulco G, Di Spiezio Sardo A, et al. Review of the safety, effi cacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Womens Health 2010;2:279-90.
22. Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531-9.
23. Belsey EM, Machin D , d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986;34:253-60. (Pubitemid 17177017)
24. Huber J , Foidart J M, Wuttke W , et a l. Effi cacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-34. (Pubitemid 30321317)
25. Bachmann G , Sulak P J, Sampson-Landers C , et a l. Effi cacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-8. (Pubitemid 39119980)
26. Anderson FD, Gibbons W , Portman D. Safety and effi-cacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229-34. (Pubitemid 43202171)
27. Akerlund M, Rode A, Westergaard J. Comparative profi les of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993;100:832-8. (Pubitemid 23280566)
28. Bayer HealthCare Pharmaceutical Inc. Natazia: Highlights of prescribing information. 2010. Accessed 19 June from:http://berlex.bayerhealthcare.com/html/ products/pi/natazia-pi.pdf
29. Mansour D , Verhoeven C , Sommer W , et al. Effi cacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011;16:430-43.
30. Westhoff C , Kaunitz A, Korver T , et a l. Effi cacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17 β-estradiol: A randomized controlled trial Obstet Gynecol 2012;119:989-99.
31. Mansour D , Inki P, Gemzell-Danielsson K. Effi cacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;15:4-16.
32. Boerrigter P J, Ellman H , Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg. Clin Ther 1999;21:118-27. (Pubitemid 29106694)
33. Hite RC, Bannemerschult R, Fox-Kuchenbecker P , et al. Large observational trial of a new low-dose oral contraceptive containing 20 micrograms ethinylestradiol and 100 micrograms levonorgestrel (Miranova) in Germany. Eur J Contracept Reprod Health Care 1999;4:7-13. (Pubitemid 29268480)
34. Archer DF, Maheux R, DelConte A , et al. A new lowdose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception 1997;55:139-44. (Pubitemid 27180388)
35. Endrikat J , Cronin M , Gerlinger C , et a l. Open, multicenter comparison of effi cacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception 2001;64:201-7. (Pubitemid 33042591)